Patents by Inventor Liudmila Prokunina

Liudmila Prokunina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Interferon-?4 (IFNL-4) protein, related nucleic acid molecules, and uses thereof
    Patent number: 10962539
    Abstract: The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 30, 2021
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Liudmila Prokunina, Thomas R. O'Brien, Brian Muchmore, Raymond P. Donnelly, Patricia A. Porter-Gill
  • A NOVEL INTERFERON-(lambda)4 (IFNL-4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF
    Publication number: 20200292546
    Abstract: The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.
    Type: Application
    Filed: January 24, 2020
    Publication date: September 17, 2020
    Inventors: Liudmila PROKUNINA, Thomas R. O'BRIEN, Brian MUCHMORE, Raymond P. DONNELLY, Patricia A. PORTER-GILL
  • Interferon-?4 (IFNL-4) protein, related nucleic acid molecules, and uses thereof
    Patent number: 10545147
    Abstract: The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: January 28, 2020
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Liudmila Prokunina, Thomas R. O'Brien, Brian Muchmore, Raymond P. Donnelly, Patricia A. Porter-Gill
  • NOVEL INTERFERON-(lambda)4 (IFNL-4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF
    Publication number: 20170254808
    Abstract: The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 7, 2017
    Inventors: Liudmila PROKUNINA, Thomas R. O'BRIEN, Brian MUCHMORE, Raymond P. DONNELLY, Patricia A. PORTER-GILL
  • Interferon-?4 (IFNL4) protein, related nucleic acid molecules, and uses thereof
    Patent number: 9678074
    Abstract: The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 13, 2017
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Liudmila Prokunina, Thomas R. O'Brien, Brian Muchmore, Raymond P. Donnelly, Patricia A. Porter-Gill
  • NOVEL INTERFERON-LAMBDA4 (IFNL4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF
    Publication number: 20150050640
    Abstract: The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Inventors: Liudmila Prokunina, Thomas R. O'Brien, Brian Muchmore, Raymond P. Donnelly, Patricia A. Porter-Gill
  • GENETIC MARKER FOR PREDICTING PROGNOSIS IN PATIENTS INFECTED WITH HEPATITIS C VIRUS
    Publication number: 20140271542
    Abstract: The present invention provides methods and materials for predicting the clinical outcome of a hepatitis C virus (HCV) infection. In particular, the invention relates to methods and materials for predicating the ability of an individual to spontaneously clear a hepatitis C virus infection. It also relates to methods and materials useful for predicting the clinical response of an individual suffering from HCV infection to administration of a therapeutic treatment. Also provided are kits for predicting the ability of an individual to spontaneously clear an HCV infection, or spontaneously clear such an infection. The methods and rated kits disclosed herein can also be used to develop a treatment plan for an individual infected with HCV, or who is at risk for developing such an infection.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 18, 2014
    Inventors: Liudmila Prokunina, Thomas O'Brien, Brian Muchmore, Raymond Donnelly